Curanex Advances Phyto-N Toward IND Submission in 2026 Annual Report

Pharmaceutical company highlights manufacturing, toxicology, and regulatory progress for lead ulcerative colitis asset.

Mar. 31, 2026 at 3:49am

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a set of polished, geometric pharmaceutical vials and beakers arranged elegantly on a clean, monochromatic seamless background, conceptually representing the strategic progress of Curanex's pharmaceutical development.Curanex's methodical progress in manufacturing, toxicology, and regulatory planning for its lead asset Phyto-N signals the company's disciplined approach to pharmaceutical development.Jericho Today

Curanex Pharmaceuticals, a pharmaceutical development company, provided a business update in its 2025 annual report, highlighting operational progress across manufacturing, nonclinical development, intellectual property, and regulatory planning as the company advances its lead asset, Phyto-N, toward a planned Investigational New Drug (IND) submission for ulcerative colitis in the fourth quarter of 2026.

Why it matters

Curanex's progress with Phyto-N represents an important milestone in the company's efforts to develop a differentiated therapeutic asset to address the significant unmet medical need in the ulcerative colitis market, which is expected to grow to $11.39 billion by 2030.

The details

Key updates include the completion of a pilot-scale GMP batch of Phyto-N to support IND-enabling studies, the successful completion of a dose-range finding toxicology study, and the filing of a PCT application to expand the company's intellectual property position. Curanex also continues to evaluate additional therapeutic opportunities beyond its lead ulcerative colitis indication.

  • In February 2026, Curanex completed a pilot-scale GMP batch of Phyto-N.
  • In 2025, Curanex advanced key CMC activities for Phyto-N, including development of quality-control methods, optimization of production processes, and scale-up to GMP-compliant pilot material.
  • In March 2025, Curanex filed a PCT application covering compositions, methods of use, and related claims across autoimmune diseases, metabolic diseases, and viral infections.

The players

Curanex Pharmaceuticals, Inc.

A pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, and the developer of the lead asset Phyto-N.

Jun Liu

Chief Executive Officer of Curanex Pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“2025 was a pivotal year for Curanex as we strengthened the operational foundation required to support a more defined pharmaceutical development strategy.”

— Jun Liu, Chief Executive Officer

“Our goal is to continue positioning Curanex as an emerging pharmaceutical company pursuing regulatory approvals for differentiated therapeutic assets with the potential to address major unmet medical needs.”

— Jun Liu, Chief Executive Officer

What’s next

Curanex plans to initiate Phase 1 clinical development of Phyto-N in Australia in the fourth quarter of 2026, subject to regulatory clearance and completion of preclinical requirements.

The takeaway

Curanex's progress with Phyto-N, including advancements in manufacturing, toxicology, and intellectual property, positions the company to potentially address the growing ulcerative colitis market and expand its broader therapeutic development platform.